glp-1 etf A Beginner's Guide to Investing in Weight Loss Drugs Mag7, AI and GLP-1: Roundhill

A 2026 systematic review and meta-analysis of randomized controlled trials confirmed that GLP-1 receptor agonists produce clinically meaningful weight loss across diverse patient populations (Ahmad et al., 2026, PMID: 41824845)

The receptor binding subsequently triggers cAMP levels, leading to an induction in insulin secretion

End User Insights Which End User Segment Led the GLP-1 Market

Common GLP-1 medications prescribed in 2025 include: Semaglutide (Wegovy, Ozempic) Tirzepatide (Mounjaro) Liraglutide (Saxenda) Peer-reviewed clinical trials published in journals such as The New England Journal of Medicine and JAMA document average body weight reductions of approximately 1022% over 612 months when GLP-1 medications are combined with lifestyle support and ongoing physician oversight

The GLP-1 receptor agonists segment dominated the market with a share of 86% in 2025, as GLP-1 receptor agonists are driving historic market expansion by transforming obesity and diabetes management into a billion-dollar global industry

In rare cases, medications can trigger inflammation in the body, including the eyes, potentially contributing to floaters through uveitis